JAMES F WINCHESTER, MD
Osteopathic Medicine at Union Sq, New York, NY
License number
New York 223317
Category
Osteopathic Medicine
Type
Internal Medicine
License number
New York 223317
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
2
10 Union Sq E BIMC- DEPT OF NEPHROLOGY, New York, NY 10003
PO Box 95000, Philadelphia, PA 19195
PO Box 95000, Philadelphia, PA 19195
Phone
(212) 420-4069
Personal information
See more information about JAMES F WINCHESTER at radaris.comName
Address
Phone
43 King St, Tonawanda, NY 14150
502 County Highway 6, Otego, NY 13825
5115 Hazel Ave, Philadelphia, PA 19143
417 Northumberland Ave, Buffalo, NY 14215
326 Juniper St APT C32, Kennett Square, PA 19348
Professional information
Owner, Quantified Value Partners, Inc.
Position:
Owner at Quantified Value Partners, Inc.
Location:
Greater New York City Area
Industry:
Investment Management
Work:
Quantified Value Partners, Inc.
since Jan 2003
-
Owner
Lazard Frères & Co., LLC
Jan 1992 - Jan 2003
-
Senior Vice President
Mabon, Nugent & Co.
- New York, NY Mar 1987 - Dec 1992
-
Limited Partner
Education:
University of Vermont 1982 - 1987
BBS, Finance Universität St. Gallen-Hochschule für Wirtschafts-, Rechts- und Sozialwissenschaften 1985 - 1986
BBS Exchange, Graduate Studies-International Banking
BBS, Finance Universität St. Gallen-Hochschule für Wirtschafts-, Rechts- und Sozialwissenschaften 1985 - 1986
BBS Exchange, Graduate Studies-International Banking
Languages:
German
Vice President At Blackrock
Position:
Fund Administration Officer at Barclays Global Investors
Location:
Greater Philadelphia Area
Industry:
Investment Management
Work:
Barclays Global Investors
since Apr 2007
-
Fund Administration Officer
Citco
2004 - 2007
-
Supervisor
Education:
Boston College 1996 - 2000
Biocompatible Devices, Systems, And Methods For Reducing Levels Of Pro-Inflammatory Or Anti-Inflammatory Stimulators Or Mediators In The Blood
US Patent:
2006005, Mar 16, 2006
Filed:
Oct 19, 2005
Appl. No.:
11/255132
Inventors:
James Brady - South Hampton NY, US
James Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyurupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank Norris - New York NY, US
Peter Quartararo - New York NY, US
Jamie Salsberg - New York NY, US
James Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyurupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank Norris - New York NY, US
Peter Quartararo - New York NY, US
Jamie Salsberg - New York NY, US
International Classification:
A61K 39/00
US Classification:
424140100
Abstract:
Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators.
Devices, Systems, And Methods For Reducing Levels Of Pro-Inflammatory Or Anti-Inflammatory Stimulators Or Mediators In The Blood
US Patent:
6878127, Apr 12, 2005
Filed:
Dec 21, 2001
Appl. No.:
10/036759
Inventors:
James A Brady - South Hampton NY, US
James F Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyurupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank M Norris - New York NY, US
Jamie A Salsberg - New York NY, US
James F Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyurupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank M Norris - New York NY, US
Jamie A Salsberg - New York NY, US
Assignee:
RenalTech International, LLC - Mammouth Junction NJ
International Classification:
A61K037/00, A61K039/00, A61K039/395, C02F001/00, B01D027/00
US Classification:
604 609, 604 616, 422 44, 4241401, 4241581, 210767, 210437
Abstract:
Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators.
Selective Adsorption Devices And Systems
US Patent:
2007009, Apr 26, 2007
Filed:
Dec 5, 2006
Appl. No.:
11/633722
Inventors:
James Brady - South Hampton NY, US
James Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyurupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank Norris - New York NY, US
Peter Quartararo - New York NY, US
Jamie Salsberg - New York NY, US
James Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyurupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank Norris - New York NY, US
Peter Quartararo - New York NY, US
Jamie Salsberg - New York NY, US
International Classification:
A61M 37/00
US Classification:
604006090
Abstract:
Intravenous, or indwelling, or integratedmulti-functional devices and systems reduce levels of a targeted compound in blood by selective adsorption. The devices and systems can be used, e.g., to reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices and systems are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices and systems serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators.
Devices, Systems, And Methods For Reducing Levels Of Pro-Inflammatory Or Anti-Inflammatory Stimulators Or Mediators In The Blood, Generated As A Result Of Extracorporeal Blood Processing
US Patent:
2002015, Oct 31, 2002
Filed:
Dec 21, 2001
Appl. No.:
10/036732
Inventors:
James Brady - South Hampton NY, US
James Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyurupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank Norris - New York NY, US
Peter Quartararo - New York NY, US
Jamie Salsberg - New York NY, US
James Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyurupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank Norris - New York NY, US
Peter Quartararo - New York NY, US
Jamie Salsberg - New York NY, US
Assignee:
Renal Tech International
International Classification:
A61K039/395, A61M037/00
US Classification:
424/140100, 604/005010
Abstract:
Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators.
Biocompatible Devices, Systems, And Methods For Reducing Levels Of Proinflammatory Or Antiinflammatory Stimulators Or Mediators In The Blood
US Patent:
2010006, Mar 18, 2010
Filed:
Jul 6, 2009
Appl. No.:
12/459680
Inventors:
James A. Brady - South Hampton NY, US
James F. Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyunupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank M. Norris - New York NY, US
Jamie A. Salsberg - New York NY, US
James F. Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyunupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank M. Norris - New York NY, US
Jamie A. Salsberg - New York NY, US
International Classification:
A61M 1/38
US Classification:
604 504
Abstract:
Devices, systems, and methods reduce levels of proinflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among proinflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of proinflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among proinflammatory or anti-inflammatory stimulators or mediators.
Devices, Systems, And Methods For Reducing Levels Of Pro-Inflammatory Or Anti-Inflammatory Stimulators Or Mediators In Blood Products
US Patent:
2002019, Dec 26, 2002
Filed:
Dec 21, 2001
Appl. No.:
10/032802
Inventors:
James Brady - South Hampton NY, US
James Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyurupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank Norris - New York NY, US
Peter Quartararo - New York NY, US
Jamie Salsberg - New York NY, US
James Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyurupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank Norris - New York NY, US
Peter Quartararo - New York NY, US
Jamie Salsberg - New York NY, US
Assignee:
Renal Tech International
International Classification:
A61K039/395, A61M037/00
US Classification:
424/140100, 604/005020
Abstract:
Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators.
Biocompatible Devices, Systems, And Methods For Reducing Levels Of Pro-Inflammatory Or Anti-Inflammatory Stimulators Or Mediators In The Blood
US Patent:
2002019, Dec 26, 2002
Filed:
Dec 21, 2001
Appl. No.:
10/036758
Inventors:
James Brady - South Hampton NY, US
James Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyurupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank Norris - New York NY, US
Peter Quartararo - New york NY, US
Jamie Salsberg - New York NY, US
James Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyurupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank Norris - New York NY, US
Peter Quartararo - New york NY, US
Jamie Salsberg - New York NY, US
Assignee:
Renal Tech International
International Classification:
A61K039/395, A61M037/00
US Classification:
424/140100, 604/005040
Abstract:
Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators.
Selective Adsorption Devices And Systems
US Patent:
2002019, Dec 26, 2002
Filed:
Dec 21, 2001
Appl. No.:
10/038053
Inventors:
James Brady - South Hampton NY, US
James Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyurupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank Norris - New York NY, US
Peter Quartararo - New York NY, US
Jamie Salsberg - New York NY, US
James Winchester - New York NY, US
Vadim Davankov - Moscow, RU
Maria Tsyurupa - Moscow, RU
Ludmila Pavlova - Moscow, RU
Frank Norris - New York NY, US
Peter Quartararo - New York NY, US
Jamie Salsberg - New York NY, US
Assignee:
Renal Tech International
International Classification:
A61K039/395, A61M037/00
US Classification:
424/140100, 604/005040
Abstract:
Intravenous, or indwelling, or integrated multi-functional devices and systems reduce levels of a targeted compound in blood by selective adsorption. The devices and systems can be used, e.g., to reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices and systems are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices and systems serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators.